Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4042395 | 0.97 | KEAP1 (0.62) | SMN1; SMN2KEAP1HRH3HPGDDUSP3 | |
| SCHEMBL22048302 | 0.93 | HRH3 (0.71) | SMN1; SMN2KEAP1HRH3HPGDDUSP3 | |
| SCHEMBL17377315 | 0.92 | KEAP1 (0.62) | SMN1; SMN2KEAP1HRH3HPGDDUSP3 | |
| SCHEMBL12937 | 0.92 | ALDH1A1 (0.54) | SMN1; SMN2KEAP1HRH3HPGDDUSP3 | |
| SCHEMBL1998867 | 0.89 | KEAP1 (0.71) | SMN1; SMN2KEAP1HRH3HPGDDUSP3 | |
| SCHEMBL13019 | 0.89 | KDM4E (0.56) | SMN1; SMN2KEAP1HRH3HPGDDUSP3 | |
| Ammonia Solution, Strong SCHEMBL9400430 | 0.87 | KEAP1 (0.68) | SMN1; SMN2KEAP1HRH3HPGDDUSP3 | |
| SCHEMBL11222517 | 0.87 | KEAP1 (0.68) | SMN1; SMN2KEAP1HRH3HPGDDUSP3 | |
| SCHEMBL13334891 | 0.85 | KEAP1 (0.48) | SMN1; SMN2KEAP1HRH3HPGDDUSP3 | |
| SCHEMBL28116939 | 0.85 | KDM4E (0.55) | SMN1; SMN2KEAP1HRH3HPGDDUSP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321067-A1 | DOSING REGIMEN COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321067-A1 | DOSING REGIMEN COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | IKZF1, IKZF2, IKZF3 | SMN1; SMN2 755/4885KEAP1 148/4885HRH3 4828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.